These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37380201)

  • 1. Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana.
    Marfoh K; Samba A; Okyere E; Acheampong F; Owusu E; Darko DNA; Zakariah J; Mensa H; Aidoo E; Mohammed Y
    BMJ Open; 2023 Jun; 13(6):e061643. PubMed ID: 37380201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.
    Subedi P; Yadav GK; Paudel B; Regmi A; Pyakurel P
    PLoS One; 2021; 16(12):e0260638. PubMed ID: 34932553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.
    Kamal D; Thakur V; Nath N; Malhotra T; Gupta A; Batlish R
    Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S283-S288. PubMed ID: 34334895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre.
    Mahadevaiah A; Doddamadaiah C; K S S; Cholenahalli Nanjappa M
    Indian J Med Microbiol; 2022; 40(2):200-203. PubMed ID: 35422343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.
    Ankrah DN; Mantel-Teeuwisse AK; De Bruin ML; Amoo PK; Ofei-Palm CN; Agyepong I; Leufkens HG
    Drug Saf; 2013 Apr; 36(4):259-66. PubMed ID: 23508545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India.
    Deb T; Garg R; Kaur M; Beniwal A; Gupta V
    Curr Drug Saf; 2022; 17(4):344-349. PubMed ID: 35049437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.
    Jose D; Dhupdale N; Cacodcar JA; Kamat U
    Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.
    Dodoo AN; Renner L; van Grootheest AC; Labadie J; Antwi-Agyei KO; Hayibor S; Addison J; Pappoe V; Appiah-Danquah A
    Drug Saf; 2007; 30(4):347-56. PubMed ID: 17408311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India.
    Jha A; Kumar P; Goel SK; Bharatwal AA; Dhamnetiya D; Singh S; Jha RP
    J Family Med Prim Care; 2024 Jan; 13(1):298-310. PubMed ID: 38482279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala.
    Jose M; Rajmohan P; Thomas J; Krishna S; Antony B; Gopinathan UU; Iyyapan EM; Porinchu RM; Jose P; Raphael L; Kuttichira P
    Curr Drug Saf; 2022; 17(4):327-334. PubMed ID: 35135453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing adverse events following COVID-19 vaccination.
    Villanueva P; McDonald E; Croda J; Croda MG; Dalcolmo M; Dos Santos G; Jardim B; Lacerda M; Lynn DJ; Marshall H; Oliveira RD; Rocha J; Sawka A; Val F; Pittet LF; Messina NL; Curtis N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2323853. PubMed ID: 38445666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.
    López-Mena D; García-Grimshaw M; Saldivar-Dávila S; Hernandez-Vanegas LE; Saniger-Alba MDM; Gutiérrez-Romero A; Carrillo-Mezo R; Valdez-Ruvalcaba HE; Cano-Nigenda V; Flores-Silva FD; Cantú-Brito C; Santibañez-Copado AM; Diaz-Ortega JL; Ceballos-Liceaga SE; Murillo-Bonilla LM; Sepulveda-Núñez AI; García-Talavera V; Gonzalez-Guerra E; Cortes-Alcala R; Lopez-Gatell H; Carbajal-Sandoval G; Reyes-Terán G; Valdés-Ferrer SI; Arauz A
    Neurology; 2022 May; 98(19):e1933-e1941. PubMed ID: 35277439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India.
    Davalagi SB; Nayak VP; Ghose A; Marakatti SS; Kasturi ES; Maganahalli AS
    J Family Med Prim Care; 2023 Nov; 12(11):2869-2874. PubMed ID: 38186765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
    Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
    BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
    Tsundue T; Namdon T; Tsewang T; Topgyal S; Dolma T; Lhadon D; Choetso T; Woesal T; Yangkyi T; Gupta A; Peters D; Paster Z; Phunkyi D; Sadutshang TD; Chaisson RE; Dorjee K
    BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35609920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.
    Adhikari S; Maharjan J; Bhattarai S; Kunwar K; Agrawal S; Dangal RK; Chapagain RH; Bista TB; Bhattarai S
    J Nepal Health Res Counc; 2024 Mar; 21(4):651-658. PubMed ID: 38616598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.